Caring Brands (CABR)
Licenses and sells topical dermatology, hair-adjunct, suncare, and OTC wellness products.
Something off on this page? Send us feedback.
Commercializes and licenses topical dermatology, hair-growth-adjunct, suncare, and OTC-wellness products through U.S. e-commerce and international partners. A small, single-segment portfolio combines direct sales with licensing royalties and relies on intellectual property, partner execution, and regulatory compliance.
Commercializes and licenses a small portfolio of patented or patent-pending topical dermatology, hair-growth-adjunct, suncare, and OTC-wellness products. Hair Enzyme Booster is a topical adjunct to FDA-approved minoxidil; Photocil, marketed as PhotoFirst in India, is a UV filter used alongside care for psoriasis, vitiligo, and atopic dermatitis; Emesyl is a licensed homeopathic nausea-relief product. CB-101 and a reformulated NoStingz sunscreen remain in the pipeline.
Sells in the United States through e-commerce and pursues international commercialization through licensees, including partners for Hair Enzyme Booster and Photocil. Its operating method pairs established mechanisms with controlled clinical testing, patent protection, and commercial-stability work. It has a single reportable segment and a three-person team; product commercialization depends on external manufacturing, distribution, territory partners, regulatory and labeling compliance, and minoxidil use for Hair Enzyme Booster.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.8M · Total debt $0 · Total assets $1.9M · Shareholders' equity $1.5M
- Revenue
- $0
- Operating income
- −$638.7K
- Net income
- −$638.7K
No dividends on record.
| Institutions | 1.74% | 157.9K shares | |
|---|---|---|---|
| 10 holders · as of Jun 30, 2026 | |||
| Other | 98.26% | 8.93M shares | |
| remainder | |||
9.09M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Franklin Resources IncInstitution | 0.40% | 35,970 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.29% | 26,155 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.27% | 24,936 | as of Jun 30, 2026 |
Susquehanna International Group, LLPInstitution | 0.23% | 20,771 | as of Jun 30, 2026 |
XTX Topco LtdInstitution | 0.20% | 18,484 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Hims & Hers Health
DTC minoxidil and telehealth contest hair-loss customer acquisition.
- Incyte
Topical therapy in vitiligo and atopic dermatitis.
- Organon
Topical VTAMA addresses psoriasis and atopic-dermatitis treatment demand.
- Pfizer
Topical nonsteroidal eczema treatment contests future CB-101 positioning.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Caring Brands | $1.31 | +0.77% | $11.8M | — | — | 10,188.8 | — |
| Hims & Hers Health | $31.43 | +7.07% | $6.55B | — | 146.1 | 2.5 | +38.3% |
| Incyte | $125.90 | +1.00% | $25.27B | 15.9 | 52.1 | 4.3 | +37.7% |
| Organon | $13.70 | +0.11% | $3.59B | 17.8 | 3.9 | 0.6 | +0.5% |
| Pfizer | $27.83 | +0.33% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| Median | 17.8 | 31.0 | 2.5 | +20.2% |